610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results
Monk P, Zhang J, Costin D, Petrylak D, Tagawa S, Karsh L, Zhu X, Linch M, Jones R, Borderies P, O'Neill V, Aggarwal R. 610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results. Annals Of Oncology 2021, 32: s651. DOI: 10.1016/j.annonc.2021.08.1123.Peer-Reviewed Original Research